Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments
暂无分享,去创建一个
[1] L Aarons,et al. Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.
[2] Lewis B. Sheiner,et al. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[3] J. Nedelman,et al. Application of Sparse Sampling Approaches in Rodent Toxicokinetics: A Prospective View , 1994 .
[4] Jon Wakefield,et al. Statistical methods for population pharmacokinetic modelling , 1998, Statistical methods in medical research.
[5] Stephen Duffull,et al. Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan , 2001, Pharmaceutical Research.
[6] Jean-Marie Rocchisani,et al. Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[7] France Mentré,et al. Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.
[8] Alain Mallet,et al. Optimal design in random-effects regression models , 1997 .
[9] France Mentré,et al. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..
[10] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.
[11] D Z D'Argenio,et al. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.
[12] France Mentré,et al. Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.
[13] Luc Pronzato,et al. Information matrices with random regressors. Application to experimental design , 2002 .
[14] H. Chernoff. Locally Optimal Designs for Estimating Parameters , 1953 .
[15] James E. Bennett,et al. The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .
[16] Stephen B. Duffull,et al. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[17] M. Rowland,et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies , 2004, European Journal of Clinical Pharmacology.
[18] Mats O. Karlsson,et al. Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[19] P. Laycock,et al. Optimum Experimental Designs , 1995 .
[20] R Gomeni,et al. Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[22] David Z. D'Argenio,et al. Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[23] France Mentré,et al. Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics* , 1995 .